A Phase 1/2a Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation, Including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (CMML)

Trial Profile

A Phase 1/2a Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation, Including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (CMML)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs E 6201 (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions; Proof of concept
  • Sponsors Strategia Therapeutics
  • Most Recent Events

    • 30 Aug 2017 Planned number of patients changed from 62 to 28.
    • 30 Aug 2017 Status changed from recruiting to discontinued.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top